MannKind Corporation (NASDAQ:MNKD) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
The following is a brief description of each matter voted upon at
our 2017 Annual Meeting of Stockholders held on May18, 2017 (the
Annual Meeting), as well as the number of votes with respect to
each matter.
|
Nominee |
Shares Voted For | Shares Withheld | Broker Non-Votes | |||||||||
|
Matthew J. Pfeffer |
29,832,716 | 2,549,260 | 43,266,903 | |||||||||
|
James S. Shannon, M.D., MRCP (UK) |
30,004,218 | 2,377,758 | 43,266,903 | |||||||||
|
Ronald Consiglio |
29,937,905 | 2,444,071 | 43,266,903 | |||||||||
|
Michael Friedman, M.D. |
29,152,535 | 3,229,441 | 43,266,903 | |||||||||
|
Kent Kresa |
29,922,285 | 2,459,691 | 43,266,903 | |||||||||
|
David H. MacCallum |
29,943,180 | 2,438,796 | 43,266,903 | |||||||||
|
Henry L. Nordhoff |
29,955,902 | 2,426,074 | 43,266,903 |
|
Our stockholders approved, on an advisory basis, the compensation of our named executive officers, as disclosed in our definitive proxy statement for the Annual Meeting, filed with the SEC on April7, 2017. The tabulation of votes on this matter was as follows: shares voted for: 29,066,237; shares voted against: 3,053,294; shares abstaining: 262,445; and broker non-votes: 43,266,903. |
|
Our stockholders indicated, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers. The tabulation of votes on this matter was as follows: shares voted for one year: 30,427,729; shares voted for two years: 345,482; shares voted for three years: 1,109,681; shares abstaining: 499,082; and broker non-votes: 43,266,905. |
|
Our stockholders ratified the selection of Deloitte Touche LLP as our independent registered public accounting firm for the fiscal year ending December31, 2017. The tabulation of votes on this matter was as follows: shares voted for: 72,709,001; shares voted against: 2,076,843; shares abstaining: 863,035; and broker non-votes: 0. |
About MannKind Corporation (NASDAQ:MNKD)
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. MannKind Corporation (NASDAQ:MNKD) Recent Trading Information
MannKind Corporation (NASDAQ:MNKD) closed its last trading session down -0.07 at 1.30 with 8,736,034 shares trading hands.